lestaurtinib has been researched along with erlotinib hydrochloride in 1 studies
Studies (lestaurtinib) | Trials (lestaurtinib) | Recent Studies (post-2010) (lestaurtinib) | Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) |
---|---|---|---|---|---|
124 | 12 | 63 | 4,353 | 786 | 3,033 |
Protein | Taxonomy | lestaurtinib (IC50) | erlotinib hydrochloride (IC50) |
---|---|---|---|
Epidermal growth factor receptor | Homo sapiens (human) | 0.1683 | |
Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 1.705 | |
Serine/threonine-protein kinase B-raf | Mus musculus (house mouse) | 0.04 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bai, Y; Bennett, K; Colinge, J; Eschrich, S; Fang, B; Grebien, F; Haura, EB; Kim, JY; Koomen, J; Li, J; Okamoto, I; Qian, X; Rawal, B; Rix, U; Schell, M; Song, L; Stukalov, A; Superti-Furga, G; Winter, G; Yoshida, T; Zhang, G | 1 |
1 other study(ies) available for lestaurtinib and erlotinib hydrochloride
Article | Year |
---|---|
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms.
Topics: Antineoplastic Agents; Carbazoles; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Furans; Gene Expression Regulation, Neoplastic; Humans; Mutation; Neoplasm Proteins; Phosphorylation; Protein Interaction Maps; Protein Kinase Inhibitors; Quinazolines; Staurosporine | 2013 |